comparemela.com

Latest Breaking News On - Department of lymphoma myeloma - Page 2 : comparemela.com

Dr Patel on the FDA Approval of Ide-Cel for Triple Class–Exposed R/R Multiple Myeloma

Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.

Texas
United-states
Krinak-patel
Department-of-lymphoma-myeloma
University-of-texas-md-anderson-cancer-center
Division-of-cancer-medicine
Cancer-medicine
Cancer-center
D
Sc
Fda-approval-of-ide-cel-

Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple Myeloma

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.

Texas
United-states
Hansc-lee
Department-of-lymphoma-myeloma
Myeloma-clinical-research
University-of-texas-md-anderson-cancer-center
Division-of-cancer-medicine
Multiple-myeloma-clinical-research
Cancer-medicine
Cancer-center
The-university-of-texas-md-anderson-cancer-center

Linvoseltamab Continues to Elicit Durable Efficacy in High-Risk Relapsed/Refractory Multiple Myeloma

Hans Lee, MD, discusses updated data from the LINKER-MM1 study in heavily pretreated relapsed/refractory multiple myeloma.

United-states
Houston
Texas
American
Hans-lee
Department-of-lymphoma-myeloma
American-society-of-hematology
University-of-texas-md-anderson-cancer-center
Myeloma-clinical-research
Regeneron-pharmaceuticals-inc
Multiple-myeloma-clinical-research
Cancer-center

Ibrutinib Plus Venetoclax Confers PFS, Response Benefit in Relapsed/Refractory MCL

Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival vs ibrutinib plus placebo in patients with relapsed/refractory MCL.

Texas
United-states
Houston
Michael-wang
Department-of-lymphoma-myeloma
Division-of-cancer-medicine
University-of-texas-md-anderson-cancer-center
Cancer-medicine
Cancer-center
Ibrutinib
Venetoclax
Ibrutibib-plus-venetoclax-

Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)

Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

California
United-states
Texas
San-diego
American
Kathryn-morris
Swaminathanp-iyer
Abhishek-maiti
Kim-hien-dao
Hemophagocytic-lymphohistiocytosis
Department-of-lymphoma-myeloma
Linkedin

vimarsana © 2020. All Rights Reserved.